RespireRx Pharmaceuticals Inc (CE) (RSPI) News

Market research report from Coherent Market Insights mentions RespireRx:

Spinal Cord Injury Therapeutics Market Projected To Witness Substantial Growth, 2024-2031:

Key Players Covered In This Report:

Teva Pharmaceutical Industries Ltd.
AbbVie Inc
Pfizer Inc.
Reddy's Laboratories Ltd
Zydus Cadila
ReNetX Bio, Inc
InVivo Therapeutics Holdings
Lineage Cell Therapeutics, Inc
Kringle Pharma Inc.
Acorda Therapeutics Inc.
Bioaxone Biosciences, Inc
RespireRx Pharmaceuticals Inc.
NervGen
Rising Pharmaceuticals, Inc
ScieGen Pharmaceuticals, Inc
MSN Laboratories Private Limited
Lannett Co Inc.


https://menafn.com/1109048318/Spinal-Cord-Injury-Therapeutics-Market-Projected-To-Witness-Substantial-Growth-2024-2031-Abbvie-Inc-Pfizer-Inc

Another indication for ampakine research?

Small-molecule targeting AMPA-mediated excitotoxicity has therapeutic effects in mouse models for multiple sclerosis

Dongxu Zhai, Shuxin Yan, James Samsom, Le Wang, Ping Su, Anlong Jiang, Haorui Zhang, Zhengping Jia Izhar Wallach, Abraham Heifets, Chiara Zanato, Chih-Chung Tseng, Albert H C Wong, Iain R Greig, Fang Liu
Affiliations Expand
PMID: 38064562 PMCID: PMC10708182 DOI: 10.1126/sciadv.adj6187
Sci Adv. 2023 Dec 8;9(49):eadj6187.
Epub 2023 Dec 8.
Abstract
While most research and treatments for multiple sclerosis (MS) focus on autoimmune reactions causing demyelination, it is possible that neurodegeneration precedes the autoimmune response. Hence, glutamate receptor antagonists preventing excitotoxicity showed promise in MS animal models, though blocking glutamate signaling prevents critical neuronal functions. This study reports the discovery of a small molecule that prevents AMPA-mediated excitotoxicity by targeting an allosteric binding site. A machine learning approach was used to screen for small molecules targeting the AMPA receptor GluA2 subunit. The lead candidate has potent effects in restoring neurological function and myelination while reducing the immune response in experimental autoimmune encephalitis and cuprizone MS mouse models without affecting basal neurotransmission or learning and memory. These findings facilitate development of a treatment for MS with a different mechanism of action than current immune modulatory drugs and avoids important off-target effects of glutamate receptor antagonists. This class of MS therapeutics could be useful as an alternative or complementary treatment to existing therapies.

Yeah, versus a grotesquely deflated valuation that costs added debt, dilution and stagnates opportunities, limits flexibility, etc.

Brilliant strategy.

What do they think fair valuation is? Surely more than the independent valuation of the OSA program considering the gabakine has the premier look exiting preclinicals and DOD funding the other platform.

They are weary of the market getting too excited, and creating grotesquely inflated hype. They seek a path to steady sustainable appreciation of the share price.

You would think listing correct management and BOD would be important!

And all 3 platforms have way outdated information!

It is illogical to cry about lack of funding and otc liquidity when you present the company like a 6th grade science project..

Yet executives, BOD, institutional have all lined up behind equity positions here last few years!! What does that tell you coupled with the lack of desire to parlay a significant DOD funded phase 2 into investor interest!!

I agree that the current state of the website is quite awful. Not only does it look amateurish, on the company management page it lists Dr. James Manuso as the CEO. He left the company on September 30, 2018.

https://www.respirerx.com/corporate/management.html

https://www.globenewswire.com/news-release/2018/06/19/1526825/0/en/RespireRx-Pharmaceuticals-Inc-Announces-Resignation-of-Dr-James-S-Manuso.html

Why did someone sell at this level to drop the pps?

That would be a start! They need an updated website to clearly highlight the asset platforms, current progress, market potential, expected milestones, etc.

An obviously they need off this EM market to bring liquidity and interest back that is essential to capitalize on opportunities to gain talent resources, collaborations and position the assets for next steps so if BP joins the picture they can maximize their position.

bottomline convey a strategy and execute it. fiduciary duty should be a proud endeavor not whatever the current status has been

Great job he needs to know we are gonna hold him to his word!

Just wrote Jeff asking if anything new that could be reported and if he was still working on shareholders news letter. We will see what happens

I recall some poster stating the company chose to "pause" the entire filing process after beginning it and getting most of the way done I think was suggested.

Maybe the company saw further progress on KRM-ll-81 was going to wait for NIH grant status in Q1 2025 and the DOD funded SCI phase 2 was likely to be pushed into 2025 as well versus EOY 2024. IF the OSA program is stalled awaiting results of this phase 1/phase 2 clinical UIC is conducting that may indicate a change of approach with OSA and hence the year long silence on that program. Silence on the EM may have been advantageous in some regard.

The ingredients are there and setting up for a very active and special 2025 as they are on the cusp of clinical trials on all 3 platforms. I hope they get some leadership help as there is no reason these assets should be valued as such. Even at a nickel and 50 million valuation seems really cheap having 3 platforms heading to clinicals where the preclincal efforts have been substaintial and successful to improve odds of success in clincals. I'm optimistic a new year will be transformative from all angles. GLTA.

"AI overview" via Google... Interesting, but could find no articles...AI overreach? But if not could be really huge!

Ampakines are drug candidates that may be useful in treating multiple sclerosis (MS) because they can modulate AMPA-type glutamate receptors (AMPARs):
AMPARs and MS
Glutamate excitotoxicity, mediated by AMPARs, can damage neurons and oligodendrocytes, which are cells that produce myelin in the central nervous system (CNS). In MS, activated immune cells release large amounts of glutamate, which can contribute to lesions.
Ampakines and AMPARs
Ampakines are positive allosteric modulators of AMPARs. They can increase cytosolic calcium levels in astrocytes, which may be sensitive to modulation by ampakines.
Ampakines as a treatment
Small-molecule antagonists of AMPA-mediated excitotoxicity may be a promising treatment for MS. These antagonists could be an alternative or complementary treatment to current immune modulatory drugs.
Glutamate homeostasis
Glutamatergic homeostasis is important for normal physiological processes. Treatment strategies that regulate glutamate homeostasis may benefit MS patients

Maybe. 8 bucks at a time while the company wastes significant time waiting for ??? To communicate and present to stakeholders and potential resources, collaborators, talent and partners?

Someone who understands the extraordinary potential, has access to EM, and wants to keep the price super low in order to accumulate more at a ridiculous price befoe RSPI explodes?

Yep. Many feel exactly the same and wondering WTF?

The company touted their exceptional SEC reporting history for years. Knew they were in line for DOD funding phase 2. They can’t hide their excitement for preclinical darling KRM-II-81 and NIH grant possibilities. And the OSA program has competitors advancing on less and RSPi’s dronabinol licensor UIC in an upcoming phase 1/2 with VA sponsorship!!

So what does it mean that they went radio silent??? IMO big time money is at the door…

Highly desirable assets is what they have presented to investors in the past! Their 3 asset platforms are only better positioned and more valuable today! Those whom invested are glad to own a piece of these assets despite it all…

Hence why this expert market is really a joke.

Who benefits from a last minute reset of the price as such on an $8 trade??

Inexcusable to end the year still on EM after half of 2024 spent there and with zero communication to shareholders. 

Hey Jeff, you're a public fking company, start acting like it. You have a fiduciary duty to shareholders. 

Said it before and I'll say it again, even the corrupt scamming clowns over at ENZC managed to keep a small bio pink current. 

Curious last trade of the year. Is this an effort to keep the price ridiculously low?

May we all prosper in the New Year which I suspect will be augmented by RSPI.

Hopefully we wake up tomorrow to the eoy share holder letter that has been swirling around

Thank you, LTListener. Happy New Year to you as well!

Happy New Year to all.

Wishing all the best of health and happiness in the new year. And just maybe, the powers at be here will turn the page and bring these premier assets to new heights in clinical trials in 2025.

The CEO of OTCMarkets provided an update to that March of 2021 article in September of 2023:
https://blog.otcmarkets.com/2023/09/14/the-expert-market-its-larger-role-post-rule-15c2-11/

https://blog.otcmarkets.com/2021/03/25/understanding-the-expert-market/

It's simple really:
OTC Markets Group operates the Expert Market.
Quotations in Expert Market securities are restricted from public viewing.
Only broker-dealers and professional or sophisticated investors are permitted to view quotations in Expert Market securities.
(above per OTCMarkets)

Bid 0.00
Ask 0.00
https://ih.advfn.com/stock-market/USOTC/respirerx-pharmaceuticals-ce-RSPI/stock-price
https://www.otcmarkets.com/stock/RSPI/quote


You can buy or sell RSPI shares if you can find a broker willing to take the trade and are willing to do so without a quote.
I believe the B/A numbers you are seeing here are actually based on the latest trading activity and not actual offers to buy and sell.

jmo

Yeah I don't understand where the b/a is coming from with no centralized platform. I wonder if what is reported here is just individual brokers b/a and it could be completely different at another brokerage.

Regardless, the EM trading is ridiculous situation for pharma assets heading into clinical trials.

10K 0.0024
1,100,000 0.0011

What b/a?

There isn't any bid and ask lol
That's the effect of being on the Expert Market.

It is all bread crumbs in terms of volume on the EM.

They need to ink some small level of funding to get the filings current and convey a strategy with the assets going forward. Use a little bit of funds and a little effort into communication and presentation of the company and the pps will be back to where they left off. Get current and then provide updates of the assets: DOD phase 2, NIH grant phase 1, OSA clinicals/FDA status, etc. By the time they exit the EM and get the clinicals in motion on these assets the stock can be .05 +/-... Let clinical success and BP partnerships bring in the big whales and send it to a quarter....

Exactly, we need to get through $0.0025.

0,0025

Well they stated in 8-k to rectify situation they were seeking funding. The most logical explanation is they have been negotiating a significant funding deal and isolating the noise on this EM and pushing deals into 2025 had significant advantages.

There is a school of thought that trading on this expert market could allow institutional and accredited type investors to absorb the float as news is continually released and the share price rises into the pennies and nickels and retail reduces their collective positions. Consolidating the float for future sustained levels of dimes and quarters as they garner success in clinical trials..

Who knows but the last 6 months has been more than irrational, I am ready to see that pendulum swing the other way!

Looking good for next year. GLTA HB

Nevertheless if the trends continues RSPI might still do well even inside the expert market. Where it’s somewhat shielded from fads, and mass hysteria.

This seems to have happened a few times already, starting with their Cortex days. This is a model case for the constitutive dead angles of finance and capitalism as it exists now. It’s an engine of creation, but things still fall in the cracks.

maybe they are waiting for a new SEC head lol

there is definitely a good reason that they needed a pause from the market, i believe those who held will be rewarded smartly!!

LT - I wonder if the strategy is to reemerge with so much to present in neuropharmacology, that they are aiming to garner enough attention in the investment world that an "irrational" price momentum will take hold and far exceed the valuation of the company. We have seen this frequently with many companies over the past 30 years.

Market report from Insight Ace Analytics mentions RespireRx:

Cannabinoid Derived Pharmaceutical Market Size, Share & Trends Analysis Report By Product (Natural (Plant-derived), Synthetic Cannabinoid), By Molecule Type (Cannabinoid Receptor Type 1 (CB1), Cannabinoid Receptor Type 2 (CB2), Others), By Disease Indication, By Region, And Segment Forecasts, 2023-2030.

Report ID : 1042 | Published : 2024-10-04 | Pages: 180 |

Competitive Landscape

Some Of The Key Players In The Cannabinoid Derived Pharmaceutical Market:

Cara Therapeutics, Inc.
Arena Pharmaceuticals (Pfizer)
Cannabics Pharmaceuticals Inc.
GW Pharmaceuticals (Jazz Pharmaceuticals)
InMed Pharmaceuticals
INSYS Therapeutics, Inc.
LaraPharm
MGC Pharmaceuticals, Ltd.
One World Cannabis
Orpheus Medica
Receptor Life Sciences
RespireRx Pharmaceuticals
Tetra Bio-Pharma
Cardiol Therapeutics
United cannabis Corporation
Zynerba Pharmaceuticals


https://www.insightaceanalytic.com/report/global-cannabinoid-derived-pharmaceutical-market-assessment/1042

ABNewswire

Key Mild Cognitive Impairment Companies: FUJIFILM Toyama Chemical Co. Ltd., Aptinyx, AgeneBio, Eisai Inc., RespireRx, Allon Therapeutics, CuraSen Therapeutics, Inc., Avraham Pharma, AstraZeneca, Sage Therapeutics, Pfizer, Materia Medica Holding, Eli Lilly and Company, GE Healthcare, Parexel, and others

https://www.abnewswire.com/pressreleases/mild-cognitive-impairment-market-to-observe-impressive-growth-during-the-forecast-period-20232032-evaluates-delveinsight-fujifilm-toyama-chemical-co-aptinyx-agenebio-eisai-inc-respirerx_690250.html

Defense world mentions RespireRx.

https://www.defenseworld.net/2024/11/23/respirerx-pharmaceuticals-otcmktsrspi-versus-syros-pharmaceuticals-nasdaqsyrs-head-to-head-survey.html

I just want to see us past 0025 lol everytime we hit it we bounce right back down to high trips lol

What's bid and ask

Check again lol

Volume: 3

Fun math...

Today's market cap is roughly 2 million at .002 per share. Truly peanuts for pharma. Especially one with 3 different assets/platforms at various clinical trial stage!!

Many mid major pharmas with similar level assets at various clinical stages would minimally trade in the 20-40 million range (2-4 pennies) AND with any BP/funding partnerships or equity stakes coupled with some clinical success can yield 200-400 million valuations. Some OTC pharmas have run up to 1 billion valuations on much less progress in the past.

The company claims to independently value the OSA program at multiples of 20 million! IMO, the gabakine preclinical compound is probably most valuable asset and of course the DOD funded phase 2 holds value as well.

smh at the potential and what flexibility and expansion opportunities would open up if these assets could sustain reasonable valuations not even talking higher end speculative valuations. Let's hope the new year opens the flood gates here for funding and communication/presentation to maximize potential of these assets as they enter clinical trials. GLTA.

Yeah I too support their scientific approach with these platforms and the reputation and achievements of those connected to those efforts is outstanding.

The reference to attracting talent and resources is on the business side. A solid leadership team would have communicated and clearly presented these assets to the investment community with continual updates. Inking a funding deal would have been very high on priority as well as maintaining fudiciary duty and completing filings. All in the effort of positioning the company to capitalize on success at each stage: preclinical thru phase 3.

LT, "hinders all flexibility to attract talent." They already have attracted a massive amount of talent by making available virtually all their ampakines for preclinical trials to university researchers all over the world. A few of the early papers out of UCI have been cited over 200 times. Incredible! I have over 100 papers, most per-reviewed. The most my early ones have been cited is 40 or so, which is a wonderful achievement...but 200+ ???

Maybe, but I think many investors are struggling understanding the strategy for the past 7 months. They have not yet inked a major funding deal to support these 3 platforms heading into clinicals. They have not presented investors or communicated to stakeholders anything at all. With the company assets continually way undervalued, it hinders all flexibility to attract talent and collaborative resources that could expand utlization of these platforms.

I think the scientific team/approach has been solid and logical in setting up these assets on best possible paths heading into clinicals. But they need business leadership to drive valuation and establish resources to advance assets through various stages of development and those potentially massive leaps in value.